Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 6/20 | 0.71 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.71 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.71 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.71 |
| ▸ | RAB9A | P51151 | 3/20 | 0.55 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.55 |
| ▸ | NPC1 | O15118 | 2/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.55 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.54 |
| ▸ | GAA | P10253 | 1/20 | 0.54 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.51 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.51 |
| ▸ | ERN1 | O75460 | 1/20 | 0.50 |
| ▸ | DRD1 | P21728 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 3/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3267842 | 0.83 | MAPT (1.00) | MAPTCYP1A2CYP2C9CYP2C19RAB9A | |
| SCHEMBL1002660 | 0.77 | MAPT (0.68) | MAPTCYP1A2CYP2C9CYP2C19RAB9A | |
| SCHEMBL11309890 | 0.77 | MAPT (0.63) | MAPTCYP1A2CYP2C9CYP2C19RAB9A | |
| SCHEMBL29708058 | 0.77 | MAPT (0.68) | MAPTCYP1A2CYP2C9CYP2C19RAB9A | |
| SCHEMBL2563368 | 0.77 | CYP1A2 (0.71) | MAPTCYP1A2CYP2C9CYP2C19RAB9A | |
| SCHEMBL2556427 | 0.76 | MAPT (0.69) | MAPTCYP1A2CYP2C9CYP2C19RAB9A | |
| SCHEMBL12290142 | 0.76 | MAPT (0.71) | MAPTCYP1A2CYP2C9CYP2C19RAB9A | |
| SCHEMBL31573992 | 0.75 | MAPT (0.60) | MAPTCYP1A2CYP2C9CYP2C19RAB9A | |
| SCHEMBL28324871 | 0.75 | MAPT (0.59) | MAPTCYP1A2CYP2C9CYP2C19RAB9A | |
| SCHEMBL10458182 | 0.74 | L3MBTL1 (0.71) | MAPTCYP1A2CYP2C9CYP2C19RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3071562-B1 | TETRAHYDRO-BENZODIAZEPINONES | HOFFMANN LA ROCHE (CH) | 2020-10-14 | — | — | EP | disclosed |
| CN-106029650-B | Tetrahydro-benzodiazepine * ketone | 豪夫迈·罗氏有限公司 | 2019-10-25 | — | — | CN | disclosed |
| US-10053431-B2 | Tetrahydro-benzodiazepinones | HOFFMANN-LA ROCHE INC. (US) | 2018-08-21 | — | — | US | disclosed |
| CN-104470905-B | The miscellaneous azepine * assimilation compounds of substitution | 霍夫曼-拉罗奇有限公司 | 2017-09-12 | — | — | CN | disclosed |
| CN-106029650-A | Tetrahydro-benzodiazepinones | 豪夫迈·罗氏有限公司 | 2016-10-12 | — | — | CN | disclosed |
| EP-3071562-A1 | TETRAHYDRO-BENZODIAZEPINONES | F. Hoffmann-La Roche AG (CH) | 2016-09-28 | — | — | EP | disclosed |
| US-20160272596-A1 | TETRAHYDRO-BENZODIAZEPINONES | HOFFMANN-LA ROCHE INC. | 2016-09-22 | — | — | US | disclosed |
| US-9394263-B2 | Substituted hetero-azepinones | F. HOFFMANN-LA ROCHE AG (CH) | 2016-07-19 | — | — | US | disclosed |
| US-20150361059-A1 | SUBSTITUTED HETERO-AZEPINONES | HOFFMAN-LA ROCHE INC. (US) | 2015-12-17 | — | — | US | disclosed |
| EP-2882725-A1 | SUBSTITUTED HETERO-AZEPINONES | F. Hoffmann-La Roche AG (CH) | 2015-06-17 | — | — | EP | disclosed |
| WO-2015071393-A1 | TETRAHYDRO-BENZODIAZEPINONES | F. HOFFMANN-LA ROCHE AG (CH) | 2015-05-21 | — | — | WO | disclosed |
| CN-104470905-A | Substituted hetero-azepinones | HOFFMANN LA ROCHE | 2015-03-25 | — | — | CN | disclosed |
| WO-2014023708-A1 | SUBSTITUTED HETERO-AZEPINONES | F. HOFFMANN-LA ROCHE AG (CH) | 2014-02-13 | — | — | WO | disclosed |
| US-4316989-A | Process for preparing difluoromethoxy derivatives of aromatic aldehydes | FIALKOV JURY A | 1982-02-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150361059-A1 | SUBSTITUTED HETERO-AZEPINONES | CCNY, CCNE1, CCND3 | MAPT 4794/4885CYP1A2 544/4885CYP2C9 713/4885 |
| US-10053431-B2 | Tetrahydro-benzodiazepinones | GABBR1, TPH1, GABBR2 | MAPT 2980/4885CYP1A2 108/4885CYP2C9 166/4885 |
| US-20160272596-A1 | TETRAHYDRO-BENZODIAZEPINONES | GABBR1, TPH1, GABBR2 | MAPT 2980/4885CYP1A2 108/4885CYP2C9 166/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.